By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Medivir AB 

Lunastigen 7

Huddinge    141 44  Sweden
Phone: 46-8-608-3100 Fax: 46-8-608-3199




GlaxoSmithKline (North Carolina) 

Peptimmune, Inc.  Development agreement for inhibitors of Cathepsin S for autoimmune and allergic diseases.

Company News
Medivir (MVRBF) Slashes Jobs in Reorg, Company to Exclusively Focus on Oncology 10/10/2016 5:53:40 AM
Medivir (MVRBF): Updated Interim Phase IIa Data Demonstrate That The Combination Of Simeprevir, Odalasvir And AL-335 Has A High Level Of Efficacy In HCV Patients 9/26/2016 10:48:40 AM
Medivir (MVRBF): MIV-711 Osteoarthritis Trial: Recommendation To Go Ahead Based On Independent Review Of Safety Data, And First Patient Enrolled In Extension Study 9/23/2016 9:55:32 AM
Medivir (MVRBF): Interim Results From Phase IIa Trial Evaluating Triple Combination Including Simeprevir Demonstrates High Level Of Efficacy In HCV Patients 9/9/2016 10:53:25 AM
Stock Pops as Medivir (MVRBF) Decides to Split into Two Companies 8/31/2016 6:02:35 AM
Medivir (MVRBF) – Interim Report, January – June 2016 8/17/2016 11:25:01 AM
Medivir (MVRBF) Licenses Rights To MIV-802 To Trek Therapeutics 8/17/2016 9:59:17 AM
Medivir (MVRBF): New Interim Phase IIa Data On Simeprevir In Combination With Other Daas Will Be Presented At The Upcoming EASL AASLD Special Conference 8/11/2016 11:55:12 AM
Medivir (MVRBF) Mulls Over Possible Corporate Split and Separate Listing of Commercial Operations 6/15/2016 6:00:24 AM
Medivir (MVRBF) Announces That Janssen R&D Decided To Start A Phase IIb Study Of Combinations Of Simeprevir, Odalasvir And AL-335 For The Treatment Of Hepatitis C 5/11/2016 11:00:59 AM